Capecitabine

Red

Brand Name(s):Xeloda

Indication:Colon cancer stage III (Adjuvant treatment)

Rationale:1,2,3

Considered:Jul-07

Review Date:Jul-23

Comments:
Jan 2020 – https://www.nice.org.uk/guidance/ng151
MHRA Drug Safety Update
Severe skin reaction associated with Xeloda,
January 2014
…………………………https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-march-2020. Patients receiving iv or intraarterial fluorouracil, or capecitabine or tegafur (both prodrugs of FU), should be tested for lack of dihydropyrimidine dehydrogenase (DPD) before starting treatment. Lack of DPD may lead to fluorouracil toxicity eg neutropenia, neurotoxicity.